GH Research PLC
NASDAQ:GHRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (29), the stock would be worth $-26.53 (235% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -21.4 | $19.6 |
0%
|
| Industry Average | 29 | $-26.53 |
-235%
|
| Country Average | 18.7 | $-17.09 |
-187%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
G
|
GH Research PLC
NASDAQ:GHRS
|
1.2B USD | -21.4 | -25.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 143.8 | 39.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 35.3 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 19.2 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 24.6 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 43.8 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 21.8 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 11.6 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13 |
| Median | 18.7 |
| 70th Percentile | 27.5 |
| Max | 2 454.8 |
Other Multiples
GH Research PLC
Glance View
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.
